Kura Oncology, Inc.

Net product revenue from COMZIFTI was $9.1 million in Q2 2026, compared with none in Q2 2025. Collaboration revenue from Kyowa Kirin was $11.8 million versus $15.3 million a year ago. R&D expense was $61.9 million compared with $62.8 million, SG&A was $31.8 million compared with $25.2 million, and net loss was $68.3 million versus $66.1 million in Q2 2025, including $8.2 million of non-cash share-based compensation. Cash, cash equivalents, and short-term investments were $519 million at June 30, 2026, down from $667.2 million at December 31, 2025. Management reiterated collaboration revenue guidance of $45 million to $55 million for 2026, $90 million to $110 million for 2027, and $90 million to $110 million for 2028, and said current cash plus anticipated $180 million in Kyowa Kirin payments should fund the Ziftomenib AML program through the first topline KOMET-017 Phase 3 results expected in 2028.

Troy Edward Wilson framed the quarter as evidence that Kura is turning product differentiation into commercial leadership. He said COMZIFTI’s early share gains validate the company’s strategy of building two differentiated growth franchises, while darlifarnib could become a second wholly owned value driver beyond the menin inhibitor franchise. His tone was confident and expansive, stressing that Kura is now stronger than a quarter ago and has the capital and execution to reach multiple milestones.

Thomas Doyle’s comments focused on the reported financials and funding runway. He cited $9.1 million of COMZIFTI product revenue, $11.8 million of collaboration revenue, $61.9 million of R&D, $31.8 million of SG&A, and $68.3 million of net loss, along with $519 million in cash and investments at quarter end. He reiterated collaboration revenue guidance for 2026 through 2028 and said the company expects its cash plus the $180 million in anticipated Kyowa Kirin payments to fund the Ziftomenib AML program through the first topline KOMET-017 results in 2028. Management also said it is being disciplined on capital allocation and that R&D spending ticked down slightly year over year.

Analysts focused on how much of COMZIFTI’s growth came from market expansion versus share gains, and management answered that it was both: share gains plus growth in the overall menin market, with no sign of inventory or stocking effects. Questions also centered on coverage, prior authorizations, and whether combination use was happening mostly in labeled relapsed/refractory NPM1 patients; management said coverage exceeds 95% of lives, access has been smooth, and the combination use reported was primarily in the relapsed/refractory population. Several questions probed KOMET-017 timing and the darlifarnib platform; management said KOMET-017 remains on track for 2028 top-line data, and that darlifarnib will start with daraxonrasib in second-line pancreatic cancer but could support additional combinations later.